InflaRx (IFRX) Share-based Compensation Growth (3y) (2020 - 2026)
InflaRx (IFRX) Share-based Compensation Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.49% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.55% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 7.39% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30.98% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.26% |
| Dec 31, 2025 | -13.78% |
| Sep 30, 2025 | -8.86% |
| Jun 30, 2025 | -18.06% |
| Mar 31, 2025 | -2.80% |
| Dec 31, 2024 | -14.54% |
| Sep 30, 2024 | -18.84% |
| Jun 30, 2024 | 3.92% |
| Mar 31, 2024 | -0.89% |
| Dec 31, 2023 | 23.06% |
| Sep 30, 2023 | 46.52% |
| Jun 30, 2023 | 20.46% |
| Mar 31, 2023 | 9.21% |
| Dec 31, 2022 | -27.97% |
| Sep 30, 2022 | -22.83% |
| Jun 30, 2022 | 4.25% |
| Mar 31, 2022 | 6.01% |
| Dec 31, 2021 | -45.10% |
| Sep 30, 2021 | -27.85% |
| Jun 30, 2021 | -31.24% |